Muscle Atrophy - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
39 Pages - GMD12073
$2,000.00

Summary

Global Markets Direct’s, ‘Muscle Atrophy - Pipeline Review, H1 2014’, provides an overview of the Muscle Atrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Muscle Atrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Muscle Atrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Atrophy Overview 6
Therapeutics Development 7
Pipeline Products for Muscle Atrophy - Overview 7
Pipeline Products for Muscle Atrophy - Comparative Analysis 8
Muscle Atrophy - Therapeutics under Development by Companies 9
Muscle Atrophy - Therapeutics under Investigation by Universities/Institutes 11
Muscle Atrophy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Muscle Atrophy - Products under Development by Companies 14
Muscle Atrophy - Products under Investigation by Universities/Institutes 15
Muscle Atrophy - Companies Involved in Therapeutics Development 16
Eli Lilly and Company 16
Rigel Pharmaceuticals, Inc. 17
Fate Therapeutics, Inc. 18
Muscle Atrophy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
LY-2495655 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Drug for Muscle Atrophy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Atropy Inhibitor - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
FT-301 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Wnt7a-­Based Protein Thearpeutics - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
L-379 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Muscle Atrophy - Recent Pipeline Updates 36
Muscle Atrophy - Dormant Projects 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products under Development for Muscle Atrophy, H1 2014 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Muscle Atrophy - Pipeline by Eli Lilly and Company, H1 2014 16
Muscle Atrophy - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 17
Muscle Atrophy - Pipeline by Fate Therapeutics, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Muscle Atrophy Therapeutics - Recent Pipeline Updates, H1 2014 36
Muscle Atrophy - Dormant Projects, H1 2014 37

List of Figures
Number of Products under Development for Muscle Atrophy, H1 2014 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax